Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice

Nature Medicine

Volumn 4, Issue 11, 1998, Pages 1253-1260

  Brown, Michael P ^a   Topham, David J ^a   Sangster, Mark Y ^a   Zhao, Jingfeng ^a   Flynn, Kirsten J ^a   Surman, Sherri L ^a   Woodland, David L ^a   Doherty, Peter C ^a   Farr, Andrew G ^b   Pattengale, Paul K ^c   Brenner, Malcolm K ^d  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GLYCOPROTEIN GP 39; IMMUNOGLOBULIN CLASS; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNODEFICIENCY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; HYPERIMMUNOGLOBULINEMIA; LYMPHOBLASTOMA; LYMPHOPROLIFERATIVE DISEASE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOBLAST; THYMUS DISEASE; TRANSGENE;

ANIMALIA; MURINAE;

EID: 0031787859     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/3233     Document Type: Article

References (52)

1. Dunn, R.J., Luedecker, C.J., Haugen, H.S., Clegg, C.H., & Farr, A.G. Thymic overexpression of CD40 ligand disrupts normal thymic epithelial organization. J. Histochem. Cytochem. 45, 129-141 (1997).
2. van Kooten. C. & Banchereau, J. CD40-CD40 ligand: a multifunctional receptor-ligand pair. Adv. Immunol. 61, 1-77 (1996).
3. Hasbold, J., Johnson-Leger, C., Atkins, C.J., Clark, E.A. & Klaus, G.B. Properties of mouse CD40: cellular distribution of CD40 and B cell activation by monoclonal anti-mouse CD40 antibodies. Eur. J. Immunol. 24, 1835-1842 (1994).
4. Grewal, I.S. & Flavell, R.A. The CD40 ligand - at the center of the immune universe? Immunol. Res. 16, 59-70 (1997).
5. Stout, R.D. & Suttles, J. The many roles of CD40 in cell-mediated inflammatory responses. Immunol. Today 17, 487-492 (1996).
6. Noelle, R.J. CD40 and its ligand in host defence. Immunity 4, 415-419 (1996).
7. Hollenbaugh, D.,Ochs, H.D., Noelle, R.J., Ledbetter, J.A. & Aruffo, A. The role of CD40 and its ligand in the regulation of the immune response. Immunol. Rev. 138, 23-37 (1994).
8. Clark, E.A. & Ledbetter, J.A. How B and T cells talk to each other. Nature 367, 425-428 (1994).
9. Kroczek, R.A.et al. Defective expression of CD40 ligand on T cells causes "X-linked immunodeficiency with hyper-IgM (HIGM1)". Immunol. Rev. 138, 39-59 (1994).
10. Fuleihan, R.L. & Geha, R.S. X-linked hyperIgM. The Immunologist 5, 133-136 (1997).
11. Malech, H.L. et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc. Natl. Acad. Sci. USA 94, 12133-12138 (1997).
12. Kohn, D.B. Gene therapy for hematopoietic and immune disorders. Bone Marrow Transplant. 18 (Suppl. 3), S55-S58 (1996).
13. Renshaw, B.R. et al. Humoral immune responses in CD40 ligand-deficient mice. J. Exp. Med. 180, 1889-1900 (1994).
14. Strzadala, L., Miazek, A., Matuszyk, J. & Kisielow, P. Role of thymic selection in the development of thymic lymphomas in TCR transgenic mice. Int. Immunol. 9, 127-138 (1997).
15. + thymocytes in the absence of clonotypic T cell antigen receptor. Eur. J. Immunol. 26, 1012-1017 (1996).
16. Sentman, C.L., Shutter, J.R., Hockenbery, D., Kanagawa, O. & Korsmeyer, S.J. Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 67, 879-888 (1991).
17. Peguet-Navarro, J. et al. CD40 ligation of human keratinocytes inhibits their proliferation and induces their differentiation. J. Immunol. 158, 144-152 (1997).
18. Heath, A.W. et al. Antibodies to murine CD40 stimulate normal B lymphocytes but inhibit proliferation of B lymphoma cells. Cell. Immunol. 152, 468-480 (1993).
19. Funakoshi, S. et al. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 83, 2787-2794 (1994).
20. (2*) thymocytes as post-selection intermediates leading to mature T cells. J. Exp. Med. 173, 323-332 (1991).
21. Kisielow, P. & von Boehmer H. Development and selection of T cells: facts and puzzles. Adv. Immunol. 58, 87-209 (1995).
22. Bunting, K.D., Sangster, M.Y., Ihle, J.N. & Sorrentino, B.P. Restoration of lymphocyte function in Janus kinase 3-deficient mice by retroviral-mediated gene transfer. Nature Med. 4, 58-64 (1998).
23. Einerhand, M.P., Bakx, T.A., Kukler, A. & Valerio, D. Factors affecting the transduction of pluripotent hematopoietic stem cells: long-term expression of a human adenosine deaminase gene in mice. Blood 81, 254-263 (1993).
24. Qazilbash, M.H. et al. Retroviral vector for gene therapy of X-linked severe combined immunodeficiency syndrome. J.Hematother. 4, 91-98 (1995).
25. Clegg, C.H. et al. Thymus dysfunction and chronic inflammatory disease in g39 transgenic mice. Int. Immunol. 9, 1111-1122 (1997).
26. Foy, T.M. et al. An essential role for gp39, the ligand for CD40, in thymic selection. J. Exp. Med. 182, 1377-1388 (1995).
27. Miller, G. in Virology 2nd edn. (eds. Fields, B.N. et al.) 563-589 (Raven, New York, 1990).
28. Cayabyab, M., Phillips, J.H. & Lanier, L.L. CD40 preferentially costimulates activation of CD4+ T lymphocytes. J. Immunol. 152, 1523-1531 (1994).
29. Armitage, R.J. et al. CD40 ligand is a potent T cell growth factor. Eur. J. Immunol. 23, 2326-2331 (1993).
30. Fanslow, W.C. et al. Recombinant CD40 ligand exerts potent biologic effects on T cells. J. Immunol. 152, 4262-4269 (1994).
31. Yang, Y. & Wilson, J.M. CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science 273, 1862-1867 (1996).
32. + T cells in MRL-lpr/lpr mice; clues from a T cell receptor β transgenic mouse. J. Immunol. 150, 3651-3667 (1993).
33. Zhou, T. et al. Kinetics of Fas-induced apoptosis in thymic organ culture. J. Clin. Immunol. 17, 74-84 (1997).
34. + tumor cells. Int. Immunol. 5, 89-96 (1993).
35. Smith, G.S., Walford, R.L. & Mickey, R.M. Lifespan and incidence of cancer and other diseases in selected long-lived inbred mice and their F1 hybrids. J. Natl. Cancer Inst. 50, 1195 (1973).
36. Hoag, W.G. Spontaneous cancer in mice. Ann. N.Y Acad. Sci. 108, 805 (1963).
37. Filipovich, A.H. et al. in The Non-Hodgkin's Lymphomas 2nd edn. (ed. McGrath, I.T.) 459-469 (Oxford University Press, New York, 1997).
38. Larson, R.C. et al. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. EMBO. J. 15, 1021-1027 (1996).
39. Anderson, W.F. Human gene therapy. Nature 392, 25-30 (1998).
40. Grossmann, M.E., Brown, M.P. & Brenner, M.K. Antitumor responses induced by transgenic expression of CD40 ligand. Hum. Gene. Ther. 8, 1935-1940 (1997).
41. Farina, S.F., Girard, L.J., Vanin, E.F., Nienhuis, A.W. & Bodine, D.M. Dysregulated expression of GATA-1 following retrovirus-mediated gene transfer into murine hematopoietic stem cells increases erythropoiesis. Blood 86, 4124-4133 (1995).
42. McLachlin, J.R., Mittereder, N., Daucher, M.B., Kadan, M. & Eglitis, M.A. Factors affecting retroviral vector function and structural integrity. Virology 195, 1-5 (1993).
43. Hanenberg, H. et al. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nature Med. 2, 876-882 (1996).
44. Heslop, H.E. et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nature Med. 2, 551-555 (1996).
45. Sorrentino, B.P. et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 257, 99-103 (1992).
46. Allan, W., Tabi, Z., Cleary, A. & Doherty, P.C. Cellular events in the lymph node and lung of mice with influenza. J. Immunol. 144, 3980-3986 (1990).
47. Flynn, K.J. & Mullbacher, A. Memory alloreactive cytotoxic T cells do not require costimulation for activation in vitro. Immunol. Cell. Biol. 74, 413-420 (1996).
48. Sangster, M., Smith, F.S., Coleclough, C. & Hurwitz, J.L. Human parainfluenza virus type 1 immunization of infant mice protects from subsequent sendai virus infection. Virology 212, 13-19 (1995).
49. Harlow, E, & Lane, D. Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory Press, 99 (1988).
50. Cole, G.A., Hogg, T.L. & Woodland, D.L. The MHC class I-restricted T cell response to Sendai virus infection in C57BL/6 mice: a single immunodominant epitope elicits an extremely diverse repertoire of T cells. Int. Immunol. 6, 1767-1775 (1994).
51. Vanin, E.F., Kaloss, M., Broscius, C. & Nienhuis, A.W. Characterization of replication-competent retroviruses from nonhuman primates with virus-induced T-cell lymphomas and observations regarding the mechanism of oncogenesis. J. Virol. 68, 4241-4250 (1994).
52. Daniels, C.A.,Bodner, S. & Trofatter, K.F. Scanning and transmission electron microscopic studies of complement-mediated lysis and antibody-dependent cell-mediated cytolysis of herpes simplex virus-infected human fibroblasts. Am. J. Pathol. 100, 663-675 (1980).